awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33412684-4781983A-3FD7-48A4-A1E8-23B1A90DB64E
Q33412684-4781983A-3FD7-48A4-A1E8-23B1A90DB64E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33412684-4781983A-3FD7-48A4-A1E8-23B1A90DB64E
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
P2860
Q33412684-4781983A-3FD7-48A4-A1E8-23B1A90DB64E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33412684-4781983A-3FD7-48A4-A1E8-23B1A90DB64E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0bdfc3ac90ee1632e81348e1fe0064023fd82d53
P2860
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.